3SBio Inc. (1530)

Overview

3SBio Inc., established in 1993 and headquartered in Shenyang, the People's Republic of China, operates as a leading investment holding company with a global reach. Its core business is focused on researching, developing, producing, and marketing a diverse range of biopharmaceutical products, targeting various therapeutic areas. The company boasts a rich portfolio of proprietary drugs and therapies, catering to patients in Mainland China and around the world. Over the years, 3SBio has established a strong reputation for its commitment to innovation and excellence in the biopharmaceutical industry. The company engages in strategic collaboration agreements with international firms, such as Toray Industries Inc., to further its research capabilities and expand its product offerings. In addition to its pharmaceutical ventures, 3SBio diversifies its operations into trading, consultation, technology, sports, financial, investment advisory, and agricultural services, showcasing its adaptability and versatility in different sectors.

Products and Services

3SBio Inc. offers a wide array of biopharmaceutical products and services, catering to various medical needs and conditions. Each product is the result of extensive research and dedication to providing effective treatment options to patients worldwide.

• TPIAO: A pioneering recombinant human thrombopoietin designed to combat both chemotherapy-induced thrombopenia and immune thrombocytopenia, showcasing the company's innovative approach to treating blood disorders.
• Cipterbin: This anti-HER2 monoclonal antibody represents a leap forward in breast cancer treatment, particularly for those with HER2-positive metastatic breast cancer, in combination with chemotherapy.
• Interferon: An injection-based therapy, featuring human interferon a2a, developed for various indications, highlighting the company's contributions to anti-viral treatments.
• Inleusin: A targeted therapy for renal cell carcinoma, melanoma, and thoracic fluid build-up due to cancer or tuberculosis, exhibiting 3SBio's commitment to oncology and severe illness management.
• YISAIPU: A receptor-antibody fusion tumor necrosis factor inhibitor, offering a novel approach to treating autoimmune diseases.
• Mendi-minoxidil tincture: An over-the-counter medicinal solution for hair loss, showcasing 3SBio’s involvement in dermatological and cosmetic conditions.
• EPIAO & SEPO: Innovations in erythropoietin injections for anemia management, underlining the company's focus on blood health.
• SPARIN: A low-molecular-weight heparin calcium injection for preventing blood clots, reflecting 3SBio’s commitment to cardiovascular health.
• Xenopax: A recombinant humanized anti-CD25 monoclonal antibody injection aimed at preventing acute rejection after renal transplantation, indicating 3SBio's involvement in transplant medicine.
• Pediatric and Disease-Specific Formulations: Products like TPO-105 Pediatric ITP, SSS12 Cinacalcet hydrochloride, and others, cater to specific patient populations, including children, demonstrating 3SBio's dedication to comprehensive care.
• Pharmaceutical Innovations: The development of AP506 Apremilast, SSS32 Tofacitinib, and MN709 Minoxidil Foam, among others, showcases the company's continuous efforts in advancing drug development and treatment methodologies.

Beyond pharmaceuticals, 3SBio extends its expertise into a variety of services, including trading, project management and consultation, technology innovation, sports management, financial and investment advisory, and agricultural services, providing a holistic approach to business and healthcare solutions.